Viking Therapeutics(US:VKTX) Prnewswireยท2025-01-29 21:05Company Overview - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] - The company has three compounds currently in clinical trials, including VK2735, VK2809, and VK0214 [3] Clinical Programs - VK2735 is a dual agonist of GLP-1 and GIP receptors, showing an encouraging safety profile and positive clinical benefits in Phase 1 and Phase 2 trials for metabolic disorders [3] - VK2809 is an orally available small molecule selective thyroid hormone receptor beta agonist, which achieved primary and secondary endpoints in a Phase 2b study for NASH and fibrosis, and demonstrated significant reductions in LDL-C and liver fat in a Phase 2a trial for NAFLD [3] - VK0214 is being developed for X-ALD, showing safety and significant reductions in VLCFAs in a Phase 1b trial [3] Upcoming Events - The company will release its financial results for Q4 and year-end 2024 on February 5, 2025, after market close [1] - A conference call to discuss these results will take place at 4:30 p.m. Eastern Time on the same day [2]